Drugs / Qizhu Yuling Prescription
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05626309 | Oct 2022 → Aug 2024 | esophageal cancer | Jie Li | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Qizhu Yuling Prescription | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05626309 ↗ |
| Known as | QZYLP | “Qizhu Yuling Prescription (QZYLP) has anticancer effects” PMID 40206581 ↗ Mar 2025 |